StockNews.AI
TEM
StockNews.AI
218 days

Tempus Announces Its First-Ever, Whole-Genome Sequencing Assay, xH

1. Tempus introduces xH, its first whole-genome sequencing test for personalized therapy. 2. xH supports clinicians in detecting clinically-relevant variants in hematological oncology. 3. Pilot study shows xH has a 98.9% concordance rate with traditional methods. 4. The test enhances treatment strategies by consolidating multiple tests into one. 5. Tempus's AI capabilities position it to transform patient care in oncology.

8m saved
Insight
Article

FAQ

Why Bullish?

Development of xH enhances Tempus' competitive edge in precision medicine, similar to past advancements.

How important is it?

The introduction of xH could significantly drive Tempus' revenue and market presence.

Why Long Term?

Long-term growth expected as xH gains clinical availability and market adoption.

Related Companies

NXTDGHDXILMN
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the company is developing its first whole-genome sequencing test, xH. This test marks Tempus’ first foray into adopting whole-genome sequencing (WGS) as a platform, supporting clinicians with detection of all clinically-relevant variants and advancing the landscape of personalized therapy, specifically in hematological oncology. With xH, Tempus builds on its AI-enabled diagnostic platform, extending a comprehensive approach that will facilitate personalized treatment decisions and a more precise understanding of patients' unique genetic profiles. xH, which is currently available for research use only (RUO) and will be clinically available within the next year, is also designed to support Tempus' biopharma collaborators, equipping researchers with the unique insights that can only come from sequencing the whole genome. “xH is our first product leveraging the full genome in our effort to provide meaningful insights into complex diseases,” said Eric Lefkofsky, Founder and CEO of Tempus. “By scaling whole-genome sequencing, we are positioned to transform patient care in hematological oncology and eventually all solid tumors, shaping the future of precision medicine and accelerating therapeutic advancements in partnership with the pharmaceutical community.” Tempus has developed a comprehensive whole-genome sequencing assay optimized for myeloid malignancies, demonstrating high sensitivity in detecting clinically-relevant genetic alterations across Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Myeloproliferative neoplasms (MPN), and other hematological malignancies. In a pilot study of 135 patients, the WGS assay identified a broad array of mutation types with a concordance rate over 98.9% compared to traditional molecular methods. Notably, WGS detected a subset of guideline-recommended structural variants (SVs) and large copy number alterations (CNAs), underscoring its potential as a cost-effective, comprehensive tool that consolidates multiple tests into a single assay. The study highlights the potential of WGS to enhance personalized treatment strategies by providing a robust, efficient approach to genomic profiling in myeloid malignancies. About Tempus Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com. Forward Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus’ industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding the potential impact of xH and other tests, the indicated use of the xH and other tests for potential clinical use, and the timing of the availability of such testing. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “going to,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release. You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus’ business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: Tempus’ financial performance; the ability to attract and retain customers and partners; managing Tempus’ growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus’ intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” in Tempus’ Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 filed with the Securities and Exchange Commission (“SEC”) as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.

Related News